In particular, baricitinib, an inhibitor of Janus Kinase (JAK)1 and JAK2 and licensed in many countries for the treatment of rheumatoid arthritis, atopic dermatitis and alopecia areata, has been reported to reduce the mortality in COVID-19 patients (28–31). This evidence concerns the gene JAK1 and atopic eczema.